Literature DB >> 25232076

Recurrence of hip instability after reconstructive surgery in patients with cerebral palsy.

Sulis Bayusentono1, Young Choi2, Chin Youb Chung2, Soon-Sun Kwon2, Kyoung Min Lee2, Moon Seok Park2.   

Abstract

BACKGROUND: Hip instability can cause major problems in children with cerebral palsy, although good outcomes of hip reconstructive surgery for hip instability have been reported. In the present study, we investigated the recurrence of hip instability after reconstructive surgery and the factors influencing this recurrence in patients with cerebral palsy.
METHODS: We examined consecutive patients with hip instability related to cerebral palsy who had undergone hip reconstructive surgery including femoral varus derotational osteotomy. The neck-shaft angle, head-shaft angle, and migration percentage were measured at each postoperative follow-up evaluation. For each Gross Motor Function Classification System (GMFCS) level, annual changes in radiographic indices were adjusted for multiple factors with use of a linear mixed model, with sex as the fixed effect and laterality and each subject as the random effects.
RESULTS: A total of 144 hips (seventy-six patients) were included in this study, and 845 radiographs were evaluated. The GMFCS level was II or III for twelve patients, IV for thirty, and V for thirty-four. The neck-shaft angle showed no significant change in the patients with GMFCS level II or III (p = 0.425), IV (p = 0.106), or V (p = 0.972). The head-shaft angle showed a significant change in those with GMFCS level IV (p = 0.008) but not in those with level II or III (p = 0.201) or V (p = 0.591). The migration percentage did not change significantly in patients with GMFCS level II or III (p = 0.742), but it increased significantly by 2.0% per year (p < 0.001) in patients with GMFCS level IV and by 3.5% per year (p = 0.003) in those with level V.
CONCLUSIONS: Periodic monitoring and follow-up for the recurrence of hip instability is important in patients with cerebral palsy and a GMFCS level of IV or V.
Copyright © 2014 by The Journal of Bone and Joint Surgery, Incorporated.

Entities:  

Mesh:

Year:  2014        PMID: 25232076     DOI: 10.2106/JBJS.M.01000

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  6 in total

1.  Blood Loss and Related Laboratory Changes after Single-Event Multilevel Surgery and Hip Reconstructive Surgery in Patients with Cerebral Palsy.

Authors:  Jae Jung Min; Soon-Sun Kwon; Kyu Tae Kim; Ki Hyuk Sung; Kyoung Min Lee; Young Choi; Moon Seok Park
Journal:  Clin Orthop Surg       Date:  2021-06-03

2.  Fate of stable hips after prophylactic femoral varization osteotomy in patients with cerebral palsy.

Authors:  Ki Hyuk Sung; Soon-Sun Kwon; Chin Youb Chung; Kyoung Min Lee; Jaeyoung Kim; Seung Yeol Lee; Moon Seok Park
Journal:  BMC Musculoskelet Disord       Date:  2018-04-27       Impact factor: 2.362

3.  Use of iliac crest allograft for Dega pelvic osteotomy in patients with cerebral palsy.

Authors:  Ki Hyuk Sung; Soon-Sun Kwon; Chin Youb Chung; Kyoung Min Lee; Jaeyoung Kim; Moon Seok Park
Journal:  BMC Musculoskelet Disord       Date:  2018-10-16       Impact factor: 2.362

4.  Combined pelvic and femoral reconstruction in children with cerebral palsy.

Authors:  Nabil Alassaf; Neil Saran; Theirry Benaroch; Reggie Cherine Hamdy
Journal:  J Int Med Res       Date:  2017-08-21       Impact factor: 1.671

5.  A balanced approach for stable hips in children with cerebral palsy: a combination of moderate VDRO and pelvic osteotomy.

Authors:  Kerstin Reidy; Christoph Heidt; Stefan Dierauer; Hanspeter Huber
Journal:  J Child Orthop       Date:  2016-06-27       Impact factor: 1.548

6.  Outcome of Femoral Varus Derotational Osteotomy for the Spastic Hip Displacement: Implication for the Indication of Concomitant Pelvic Osteotomy.

Authors:  Hoon Park; Sharkawy Wagih Abdel-Baki; Kun-Bo Park; Byoung Kyu Park; Isaac Rhee; Seung-Pyo Hong; Hyun Woo Kim
Journal:  J Clin Med       Date:  2020-01-17       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.